← View All News

Andropause

Summary

This article reviews andropause (late-onset hypogonadism), outlines the impact of testosterone decline on men’s health, and examines evidence-based clinical strategies including testosterone replacement therapy, lifestyle interventions, and personalized treatment options.

Table of Contents

Introduction: What Is Andropause?

Symptoms of Low Testosterone

Causes of Low Testosterone in Men

Diagnosis of Testosterone Deficiency

Treatment for Low Testosterone

Lifestyle Modifications for Low Testosterone

Conclusion

References

Introduction: What Is Andropause?

Andropause, sometimes called male menopause, refers to the gradual decline of testosterone that occurs with aging. Clinically, this condition is more accurately described as late-onset hypogonadism (LOH) or age-related testosterone deficiency. Testosterone is the primary male sex hormone, regulating sexual development, sperm production, muscle mass, fat distribution, bone strength, mood, and energy. It also supports immune function, red blood cell production, stress resilience, and cognitive clarity [1–6]. Because testosterone influences many systems, declining levels can affect physical health, mental performance, and overall well-being.

Symptoms of Low Testosterone

Common clinical manifestations include fatigue, reduced muscle strength, increased fat, bone loss with greater fracture risk, mood disturbances such as irritability or depression, diminished libido, and sexual dysfunction. Some men may also present with anemia, abnormal cholesterol values, or hair thinning [7–9]. These features often overlap with those linked to chronic stress, poor nutrition, inactivity, or environmental toxin exposure [10–14] and may be mimicked by medical conditions including diabetes, thyroid disorders, depression, medication side effects, or excessive alcohol use [15–18]. Given this overlap, careful evaluation of underlying causes is essential before confirming a diagnosis of testosterone deficiency.

Causes of Low Testosterone in Men

Testosterone deficiency occurs when the hypothalamic-pituitary-testicular (HPT) axis is disrupted, resulting in hypogonadism. Primary hypogonadism is caused by testicular dysfunction, secondary hypogonadism by pituitary or hypothalamic dysfunction, and idiopathic hypogonadism when the cause is unknown. Risk factors include congenital disorders, testicular injury, prior testosterone therapy, chronic illness, obesity, cardiovascular disease, alcoholism, and chronic stress [19]. Understanding these potential contributors helps guide the next step, which is confirming the diagnosis through appropriate clinical evaluation.

Diagnosis of Testosterone Deficiency

Diagnosis requires more than symptoms alone. The standard approach includes a review of medical and sexual history, a physical examination, and laboratory confirmation. Guidelines define testosterone deficiency as total serum testosterone below 300 ng/dL on two early-morning tests, in the presence of compatible clinical symptoms. Adjunctive laboratory testing can then help determine etiology and the appropriateness of testosterone replacement therapy [20]. Once testosterone deficiency is confirmed through both clinical and laboratory evaluation, providers can proceed to individualized treatment planning.

Treatment for Low Testosterone

Testosterone replacement therapy (TRT) is the standard treatment for men with symptomatic hypogonadism. The goal is to restore physiologic testosterone levels and relieve symptoms while minimizing risks [21, 22]. Evidence shows TRT can improve psychological distress and health-related quality of life in late-onset hypogonadism [23], increase libido and favorably affect body composition [24, 25]. Outcomes for metabolic parameters are mixed in hypogonadal men with type 2 diabetes. Some studies show improvement of metabolic parameters such as insulin resistance, glycemic control, visceral adiposity, and cholesterol [26, 27], while others do not [28].

Several forms of testosterone therapy are available, each with unique advantages and considerations for patient adherence, convenience, and safety. Intramuscular injections are one of the most common options. Testosterone cypionate can be injected into the muscle, with levels peaking in the days after injection and then declining over approximately two weeks. This can result in fluctuations in mood, libido, and energy [29]. Dosing and frequency can be adjusted as needed.

Topical testosterone treatments are often applied directly to the skin once daily, where the hormone is absorbed through the surface into systemic circulation. Transference to partners, children, or pets may occur for up to 12 hours after application [30], so precautions such as strategic site selection, careful hand-washing, and the use of clothing barriers are essential. Compounded creams can be tailored to meet patient-specific requirements, offering flexibility in dosing and formulation that commercial products may not provide.

Subcutaneous hormone pellets are implanted under the skin during a minor in-office surgical procedure. They deliver a continuous release of hormones over a three- to six-month period, helping to maintain steady hormone levels [31]. The main advantages of pellet therapy can include infrequent dosing, improved compliance for patients who prefer not to manage daily or weekly administration, and the absence of transference risk. Together, these delivery options allow providers to match treatment to patient preference and lifestyle.

Lifestyle Modifications for Low Testosterone

In addition to medical therapy, lifestyle interventions play a key role in managing low testosterone. Resistance training using compound lifts (e.g., squats, deadlifts, bench press, pull-ups) at moderate to high intensity with short rest periods has been shown to produce significant short-term increases in testosterone, although overtraining and endurance training may reduce levels [32].

Adequate sleep of seven to nine hours is essential, as poor sleep is strongly linked to reduced testosterone. Chronic stress elevates cortisol, which suppresses testosterone, making stress management techniques such as mindfulness or regular physical activity important [33].

In men with obesity-related functional hypogonadism, weight loss achieved through lifestyle interventions is considered first-line therapy and has been shown to restore normal testosterone levels. Among dietary approaches, hypocaloric, high-protein, Mediterranean-style diets appear most effective, with evidence of improvement in testosterone concentrations, the testosterone to estradiol ratio, sexual function, and sperm quality [34, 35]. Together, these lifestyle strategies not only complement testosterone replacement therapy when indicated but also provide a sustainable foundation for improving hormone balance, metabolic health, and overall quality of life.

Conclusion

Andropause, or late-onset hypogonadism, represents a complex interplay of age-related hormonal decline, comorbid conditions, and lifestyle factors that can significantly impact men’s health and quality of life. Accurate diagnosis requires careful assessment of symptoms, risk factors, and laboratory testing to distinguish testosterone deficiency from conditions with similar presentations. Once confirmed, a comprehensive management plan may include both medical therapy and evidence-based lifestyle interventions. Testosterone replacement therapy remains the standard of care for symptomatic hypogonadism, with multiple delivery options that allow providers to tailor treatment to individual patient preferences and needs. At the same time, weight management, exercise, stress reduction, and restorative sleep form the essential foundation of long-term hormone balance and overall health.

Carie Boyd Pharmaceuticals partners with providers by offering testosterone injections, compounded creams, subcutaneous pellets, and oral hormone formulations, along with adjunctive therapies and clinical consultations to support comprehensive hormone management for men and women. With personalized treatment strategies and the integration of lifestyle support, providers can help patients restore vitality, improve physical and psychological well-being, and achieve sustainable health outcomes.

  1. Kim, M., Golan, R., Narasimman, M., & Ramasamy, R. (2022). Is there an andropause (late-onset hypogonadism), and if so, what tissues are affected and how? In B. Robaire & P. Chan (Eds.), Handbook of andrology (3rd ed., pp. 334–338). The American Society of Andrology.
  2. Sisk, C., Lonstein, J., & Gore, A. (2013). Critical periods during development: Hormonal influences on neurobehavioral transitions across the life span. In Hormones, brain and behavior (pp. 2049–2086). Springer. https://doi.org/
  3. Borst, S. E., & Mulligan, T. (2007). Testosterone replacement therapy for older men. Clinical interventions in aging, 2(4), 561–566. https://doi.org/10.2147/cia.s1609
  4. Warren, A. M., & Grossmann, M. (2022). Haematological actions of androgens. Best practice & research. Clinical endocrinology & metabolism, 36(5), 101653. https://doi.org/
  5. Trigunaite, A., Dimo, J., & Jørgensen, T. N. (2015). Suppressive effects of androgens on the immune system. Cellular immunology, 294(2), 87–94. https://doi.org/
  6. Ilkevič, E., Jašinskaitė, E., Gaižauskaitė, R., & Grikšienė, R. (2025). Testosterone and cortisol moderate perception of mild psychosocial stress in young males. Psychoneuroendocrinology, 180, 107557. https://doi.org/
  7. Sternbach H. (1998). Age-associated testosterone decline in men: clinical issues for psychiatry. The American journal of psychiatry, 155(10), 1310–1318. https://doi.org/
  8. Khera M. (2013). Patients with testosterone deficit syndrome and depression. Archivos espanoles de urologia, 66(7), 729–736.
  9. Tsujimura A. (2013). The Relationship between Testosterone Deficiency and Men’s Health. The world journal of men’s health, 31(2), 126–135. https://doi.org/
  10. Pressman, A., Hernandez, A., & Sikka, S. C. (2018). Lifestyle stress and its impact on male reproductive health. In S. C. Sikka & W. J. G. Hellstrom (Eds.), Bioenvironmental issues affecting men’s reproductive and sexual health (pp. 73–83). Academic Press. https://doi.org/
  11. Shalaby, H., Dick, B. P., & Kim, J. (2022). Impact of environmental and dietary issues on male sexual health. Current Sexual Health Reports, 14(1), 9–16. https://doi.org/
  12. Roychoudhury, S., Chakraborty, S., Choudhury, A. P., Das, A., Jha, N. K., Slama, P., Nath, M., Massanyi, P., Ruokolainen, J., & Kesari, K. K. (2021). Environmental Factors-Induced Oxidative Stress: Hormonal and Molecular Pathway Disruptions in Hypogonadism and Erectile Dysfunction. Antioxidants (Basel, Switzerland), 10(6), 837. https://doi.org/
  13. Roychoudhury, S., & Bhattacharjee, R. (2018). Environmental issues resulting in andropause and hypogonadism. In S. C. Sikka & W. J. G. Hellstrom (Eds.), Bioenvironmental issues affecting men’s reproductive and sexual health (pp. 261–273). Academic Press. https://doi.org/
  14. De Silva, N. L., Papanikolaou, N., Grossmann, M., Antonio, L., Quinton, R., Anawalt, B. D., & Jayasena, C. N. (2024). Male hypogonadism: pathogenesis, diagnosis, and management. The lancet. Diabetes & endocrinology, 12(10), 761–774. https://doi.org/
  15. Kapoor, D., Aldred, H., Clark, S., Channer, K. S., & Jones, T. H. (2007). Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: Correlations with bioavailable testosterone and visceral adiposity. Diabetes Care, 30(4), 911–917. https://doi.org/
  16. Meikle A. W. (2004). The interrelationships between thyroid dysfunction and hypogonadism in men and boys. Thyroid : official journal of the American Thyroid Association, 14 Suppl 1, S17–S25. https://doi.org/
  17. Indirli, R., Lanzi, V., Arosio, M., Mantovani, G., & Ferrante, E. (2023). The association of hypogonadism with depression and its treatments. Frontiers in endocrinology, 14, 1198437. https://doi.org/
  18. Duca, Y., Aversa, A., Condorelli, R. A., Calogero, A. E., & La Vignera, S. (2019). Substance Abuse and Male Hypogonadism. Journal of clinical medicine, 8(5), 732. https://doi.org/
  19. Mayo Clinic. (n.d.). Male hypogonadism: Causes. Mayo Clinic. http://www.mayoclinic.com/
  20. Mulhall, J. P., Trost, L. W., Brannigan, R. E., Kurtz, E. G., Redmon, J. B., Chiles, K. A., Lightner, D. J., Miner, M. M., Murad, M. H., Nelson, C. J., Platz, E. A., Ramanathan, L. V., & Lewis, R. W. (2018). Evaluation and Management of Testosterone Deficiency: AUA Guideline. The Journal of urology, 200(2), 423–432. https://doi.org/
  1. Snyder, P. J., Peachey, H., Berlin, J. A., Hannoush, P., Haddad, G., Dlewati, A., Santanna, J., Loh, L., Lenrow, D. A., Holmes, J. H., Kapoor, S. C., Atkinson, L. E., & Strom, B. L. (2000). Effects of testosterone replacement in hypogonadal men. The Journal of clinical endocrinology and metabolism, 85(8), 2670–2677. https://doi.org/
  2. Bassil, N., Alkaade, S., & Morley, J. E. (2009). The benefits and risks of testosterone replacement therapy: a review. Therapeutics and clinical risk management, 5(3), 427–448. https://doi.org/
  3. Zhang, X. W., Liu, Z. H., Hu, X. W., Yuan, Y. Q., Bai, W. J., Wang, X. F., Shen, H., & Zhao, Y. P. (2012). Androgen replacement therapy improves psychological distress and health-related quality of life in late onset hypogonadism patients in Chinese population. Chinese medical journal, 125(21), 3806–3810.
  4. Andrade, E. S., Jr, Clapauch, R., & Buksman, S. (2009). Short term testosterone replacement therapy improves libido and body composition. Arquivos brasileiros de endocrinologia e metabologia, 53(8), 996–1004. https://doi.org/
  5. Wang, C., Swerdloff, R. S., Iranmanesh, A., Dobs, A., Snyder, P. J., Cunningham, G., Matsumoto, A. M., Weber, T., Berman, N., & Testosterone Gel Study Group (2000). Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. The Journal of clinical endocrinology and metabolism, 85(8), 2839–2853. https://doi.org/
  6. Kapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H. (2006). Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European journal of endocrinology, 154(6), 899–906. https://doi.org/
  7. Wittert, G., Bracken, K., Robledo, K. P., Grossmann, M., Yeap, B. B., Handelsman, D. J., Stuckey, B., Conway, A., Inder, W., McLachlan, R., Allan, C., Jesudason, D., Fui, M. N. T., Hague, W., Jenkins, A., Daniel, M., Gebski, V., & Keech, A. (2021). Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. The lancet. Diabetes & endocrinology, 9(1), 32–45. https://doi.org/10.1016/S2213-8587(20)30367-3.
  8. Bhasin, S., Lincoff, A. M., Nissen, S. E., Wannemuehler, K., McDonnell, M. E., Peters, A. L., Khan, N., Snabes, M. C., Li, X., Li, G., Buhr, K., Pencina, K. M., & Travison, T. G. (2024). Effect of Testosterone on Progression From Prediabetes to Diabetes in Men With Hypogonadism: A Substudy of the TRAVERSE Randomized Clinical Trial. JAMA internal medicine, 184(4), 353–362. https://doi.org/10.1001/jamainternmed.2023.7862
  9. Nankin H. R. (1987). Hormone kinetics after intramuscular testosterone cypionate. Fertility and sterility, 47(6), 1004–1009.
  10. Stahlman, J., Britto, M., Fitzpatrick, S., McWhirter, C., Testino, S. A., Brennan, J. J., & Zumbrunnen, T. L. (2012). Serum testosterone levels in non-dosed females after secondary exposure to 1.62% testosterone gel: effects of clothing barrier on testosterone absorption. Current medical research and opinion, 28(2), 291–301. https://doi.org/10.1185/03007995.2011.652732
  1. McCullough A. (2014). A Review of Testosterone Pellets in the Treatment of Hypogonadism. Current sexual health reports, 6(4), 265–269. https://doi.org/
  2. Riachy, R., McKinney, K., & Tuvdendorj, D. R. (2020). Various Factors May Modulate the Effect of Exercise on Testosterone Levels in Men. Journal of functional morphology and kinesiology, 5(4), 81. https://doi.org/
  3. Wrzosek, M., Woźniak, J., & Włodarek, D. (2020). The causes of adverse changes of testosterone levels in men. Expert review of endocrinology & metabolism, 15(5), 355–362. https://doi.org/
  4. Corona, G., Rastrelli, G., Monami, M., Saad, F., Luconi, M., Lucchese, M., Facchiano, E., Sforza, A., Forti, G., Mannucci, E., & Maggi, M. (2013). Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. European journal of endocrinology, 168(6), 829–843. https://doi.org/
  5. Giagulli VA, Castellana M, Murro I, Pelusi C, Guastamacchia E, Triggiani V, De Pergola G. The Role of Diet and Weight Loss in Improving Secondary Hypogonadism in Men with Obesity with or without Type 2 Diabetes Mellitus. Nutrients. 2019 Dec 5;11(12):2975. doi: 10.3390/nu11122975. PMID: 31817436; PMCID: PMC6950423.
Consult a Pharmacist